Shares of Teva Pharmaceutical moved lower heading into the close, which is being attributed to an FDA inspection letter that was sent to Celltrion following an inspection conducted on July 9-17. RBC Capital analyst Randall Stanicky has previously said on March 26 that he was concerned about fremanezumab given Celltrion’s outstanding warning letter. In October of 2016, Celltrion and Teva had announced that the companies entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.